Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
Novartis transforms its Global Health & Corporate Responsibility organization.
Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.
The most lethal strain could be eliminated by 2030, but major hurdles remain.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.